Sells ANKTIVA, an immune-activating cancer therapy, and develops vaccines, immune-modulating drugs and cell therapies for people with cancer and infectious diseases.
10-K for FY2025, filed Feb 23, 2026
Healthcare distributors and a specialty pharmacy pay for ANKTIVA when it is delivered. Other revenue comes from bioreactors and consumables, and fees for cell-line licenses, including annual research fees and royalties on licensees’ sales.
10-K for FY2025, filed Feb 23, 2026The company recognizes product revenue from product sales when obligations under the terms of a contract with a customer are satisfied.…View ↗
Prior to the approval of ANKTIVA for commercial sale, we primarily generated revenues from non-exclusive license agreements related to our…View ↗
We sell our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies and third parties. The arrangements…View ↗
The company also has nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies that grant them…View ↗
Our license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some…View ↗
10-K for FY2025, filed Feb 23, 2026
FY2025 revenue by product or service ↗$113.3M
10-K for FY2025, filed Feb 23, 2026
$113.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
100%
FY2022: 0.0%
|
Product revenue, net, FY2025
$113M Sources
|
Sold outright |
|
Other revenues
Mix
|
0.3%
FY2022: 100%
|
Other revenues, FY2025
$306K Sources
|
Mix |
Specialty pharmaceutical distributors and a specialty pharmacy buy ANKTIVA for distribution to healthcare institutions and end users. Other customers include companies buying bioreactors and consumables or licensing cell lines and related intellectual property.
10-K for FY2025, filed Feb 23, 2026The company recognizes product revenue from product sales when obligations under the terms of a contract with a customer are satisfied.…View ↗
We sell our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies and third parties. The arrangements…View ↗
The company also has nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies that grant them…View ↗
10-K for FY2025, filed Feb 23, 2026
The company relies heavily on a limited number of customers to market and distribute ANKTIVA to various healthcare institutions or end…View ↗
No. It lost $351.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$184.6MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Oct 14, 2026
On October 14, 2026, ImmunityBio, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA)…View ↗
8-K, filed May 18, 2026
On May 14, 2026, ImmunityBio, Inc., a Delaware corporation (“ImmunityBio” or the “Company”), entered into an exclusive development and…View ↗
Growing. Revenue grew 121.3x in 4 years, from $934K in FY2021 to $113.3M in FY2025, about 232% a year.
From development to commercial sales
The earlier report described ImmunityBio as a clinical-stage company developing therapies and vaccines. The latest report describes ANKTIVA as an approved product being commercialized, alongside a pipeline of other therapies.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 23, 2026ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and…View ↗
A new BCG supply business
The earlier report focused on developing its own immunotherapy and vaccine platforms. The latest report also describes commercial efforts to supply BCG alongside ANKTIVA, including an agreement for Tokyo-strain BCG.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 23, 2026Our business is based on the foundation of multiple platforms that collectively act on the entire immune response with the goal of…View ↗
ANKTIVA is our lead biologic product and a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. We are…View ↗
We are seeking to expand development of ANKTIVA in combination with current standard-of-care therapies across multiple solid and liquid…View ↗
Prior to the approval of ANKTIVA for commercial sale, we primarily generated revenues from non-exclusive license agreements related to our…View ↗
Competes with Merck, Ferring, Janssen Biotech, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis, Kite/Gilead, and Legend
10-K for FY2025, filed Feb 23, 2026Approved Therapies: Beyond ANKTIVA being approved for BCG-unresponsive NMBIC CIS with or without papillary tumors, pembrolizumab (KEYTRUDA…View ↗
Loading...